Rotavirus Vaccine Phase III Trials May Require 60,000 - 100,000 Patients

Rotavirus vaccine Phase III studies may require between 60,000 and 100,000 patients to address rare adverse event risks, Thomas Fleming, PhD, University of Washington, said during the Vaccines & Related Biological Products Advisory Committee meeting May 11.